Dr. Reddy s Laboratories PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM

Similar documents
peace of mind For from development to commercial supply

Security and Risk Assessment in GDPR: from policy to implementation

the SPD company Dr Clive Simon, Principal, The SPD Company.

Authors Heidi Gautschi Alexandre Raynaud Damien Vossion Michael Wade. Digital Patient Engagement. Insights for the Pharmaceutical Industry

Where the brightest scientific minds thrive. IMED Early Talent and Post Doc programmes

Leader in Pharmaceutical Films

Our position. ICDPPC declaration on ethics and data protection in artificial intelligence

Medical Device Usability Engineering. Product and Service Design Innovation Consultancy

Feature. Accelerate Business Development Contributing to Further Enhance Ophthalmic Treatment in Asia. 2020, our goal is to become #1 in

Translational scientist competency profile

Industry at a Crossroads: The Rise of Digital in the Outcome-Driven R&D Organization

PROGRAM ANNOUNCEMENT. New Jersey Institute of Technology. MSPhM Systems Engineering. Newark. Fall 2008

FDA Centers of Excellence in Regulatory and Information Sciences

Bayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division

Scottish Health and Life Sciences Innovation Workshop. The Industrial Strategy Challenge Fund

Introducing Elsevier Research Intelligence

Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum

A Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data

JUST SCRATCHING THE SERVICE

(Fig.) JPMA Industry Vision 2025

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

Making lives better every day. This is UCB

The Industrial Strategy Challenge Fund

Update on Progress Implementing the LSIF Anti- Counterfeit Medicines Action Plan

Presentation. March 2007

Table Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...

Enabling ICT for. development

Plant Protection Products. Veterinary Medicines. Biocides. Chemicals. Branch out and broaden your horizons

The EFPIA Perspective on the GDPR. Brendan Barnes, EFPIA 2 nd Nordic Real World Data Conference , Helsinki

Create for the future

PROGRAM OBJECTIVES-M.PHARM (PHARMACEUTICAL ANALYSIS)

Global citizenship at HP. Corporate accountability and governance. Overarching message

Research Brief. Clinicians and life sciences companies working together: What types of relationships do clinicians find most appealing?

ADVANCING KNOWLEDGE. FOR CANADA S FUTURE Enabling excellence, building partnerships, connecting research to canadians SSHRC S STRATEGIC PLAN TO 2020

Technology and Innovation in the NHS Scottish Health Innovations Ltd

API hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy.

Foreign Filing Strategies - Considerations in Protecting Your Patents Globally

James R. Cotto Corporate Client Group Director Senior Vice President Senior Investment Management Consultant Wealth Management for Entertainers and

Integrate, validate, and implement

Pharmaceutical Promotion in Medical (and Pharmacist) Training in the Netherlands: Readiness for Curriculum Change

Clinical Forum Attendee Sample Job Titles

SHTG primary submission process

Corporate Mind 2015 Corporate Responsibility Report

Pharmaceutical Products and Services

THE CENTER FOR WOMEN S ENTREPRENEURIAL LEADERSHIP AT BABSON

Healthcare and Life Sciences

Sustainable Society Network+ Research Call

Q&A. Eric Quint Chief Design Officer, 3M company

Privacy and the EU GDPR US and UK Privacy Professionals

Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships

NUS Institute of Systems Science appoints Janet Ang as new Chairperson

Public Private Partnerships & Idea selection

Brief to the. Senate Standing Committee on Social Affairs, Science and Technology. Dr. Eliot A. Phillipson President and CEO

Success factor technology

INTEL INNOVATION GENERATION

J.P. Morgan Healthcare Conference Summary Transcript

RESEARCH AND INNOVATION STRATEGY

SCIENCE + BEAUTY. Technical Expertise for the Beauty Industry. 6 pages total

MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)

INTRODUCTION OUR VISION: We are driven to be a preeminent college of pharmacy in the world. Our world begins in Iowa. OUR MISSION:

Higher School of Economics, Vienna

Vetter. The experts in complex development, aseptic manufacturing and packaging. Facts figures data 2018

A manifesto for global sustainable health. Sustainable Health Symposium Cambridge, UK 25th July 2017

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

Publication Date Reporter Pharma Boardroom 24/05/2018 Staff Reporter

What We Heard Report Inspection Modernization: The Case for Change Consultation from June 1 to July 31, 2012

Patented Medicine Prices Review Board P M P R B GUIDELINES REFORM. 15 th Annual Market Access Summit. Douglas Clark Executive Director PMPRB

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

MASTER DATA MANAGEMENT 7 QUESTIONS TO CONSIDER

OUR VISION. Explaining the WHY, the WHAT and the HOW of SBM Offshore.

QUESTIONS & ANSWERS 1

CeQur establishes Wales subsidiary

Great Minds. Internship Program IBM Research - China

Overview of Health Technology Assessment (HTA) from Asia Pacific Perspective

Response to the Western Australian Government Sustainable Health Review

With you from pit to port. Mining & Metallurgy

Course Outline and Syllabus for Students

Lupin Limited Annual Results FY12. Investor Presentation May being

Intellectual Property

International Research Collaboration. Dr Claire McNulty British Council

Coatings technology overview

JOHN JACK R. TUPMAN, JR CURRICULUM VITAE

Welcome to Althea. Welcome to the future of integrated healthcare technology management

Turning the wheels of your success

Future of Pharmaceutical Quality and the Path to Get There

Pharma Clean Assurance Programme.

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei

RADIOLOGY August 2017

SCIENTIFIC INTEGRITY

Delicate tasks should be entrusted to safe hands: Medical gases from Messer.

CEOCFO Magazine. Pat Patterson, CPT President and Founder. Agilis Consulting Group, LLC

A Research and Innovation Agenda for a global Europe: Priorities and Opportunities for the 9 th Framework Programme

Digitisation Plan

Science Integration Fellowship: California Ocean Science Trust & Humboldt State University

AkzoNobel Aerospace Coatings. Global Training Program

INTELLECTUAL PROPERTY POLICY

Medical Education Activities

Progressive Licensing and the Modernization of the Canadian Regulatory Framework

National Innovation System of Mongolia

Achievements of FP7 examples that make us proud

Transcription:

Dr. Reddy s Laboratories PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-2020

Since 1984, Dr. Reddy s has succeeded in its purpose of providing affordable and innovative medicines for healthier lives. Globally headquartered in Hyderabad, India, Dr. Reddy s was founded in 1984, established a US presence in 1992, and won its first patent challenge in the US in 2001. As a fully integrated pharmaceutical company that is driven by the belief that Good Health Can t Wait, our purpose is to accelerate access to affordable and innovative medicines through our core businesses: Active Pharmaceutical Ingredients Custom Pharmaceutical Services Global Generics OTC products Differentiated Formulations Biologics Our products are marketed globally, and our strong portfolio of businesses, geographies and products allows us to provide affordable medication to people across the world, regardless of geographic and socio-economic barriers. OUR BELIEF Our belief lies at the core of our work and serves as an overarching conviction for all 20,000 of us. This is what makes up our DNA at Dr. Reddy s Laboratories. It s a belief rooted in our empathy with our patients and partners. A belief which stems from our deep understanding of patient needs, and our determination to meet those needs by resolving challenges that only a few can. A belief that rests on our dynamism in serving those unmet and under-met needs with speed and agility. We are driven by the fundamental belief that Good Health Can t Wait. Good Health is always the goal. We are in the business of good health, and we don t see medicines as just molecules, but as tools that will help people get back their health and promote wellness among them. Can t Wait captures our commitment to act with speed, along with our partners to find innovative solutions that address the needs of patients, and accelerate the much needed medicines to a large number of people around the world. PAGE 2 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20

OUR PRINCIPLES Our principles serve to provide both guidance for our current behavior and inspiration for our future actions. To help us guide in living up to our brand belief at every touch point we have identified two principles: Empathy We understand the needs of our patients and partners better than others. Dynamism We solve challenges that only a few can, and do this with agility. OUR PURPOSE Our purpose is about why we do what we do. It stems from our Belief and Principles. We accelerate access to affordable and innovative medicines because Good Health Can t Wait. PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20 PAGE 3

OUR PROMISES If our purpose is about why we do what we do, then our promises must make clear what we do. It s about what we offer, about what commitments we make to our customers. It will always be the reason why our customers choose us over the others. The 5 promises that we must make and keep at all times are: I) Bringing expensive medicine within reach II) Address unmet patient needs III) Help patients manage diseases better IV) Enable and help our partners to ensure availability of drugs V) Work with our partners and help them be successful OUR VALUES Each of us at Dr. Reddy s is driven by the urgency and belief that Good Health Can t Wait. Our patients trust our medicines and we believe that this trust must be earned every single day. We continually remind ourselves that the interests of our patients must always come first. In pursuit of this, we believe in creating an environment of innovation and learning, as we push ourselves to reach higher levels of excellence. To aid that, here are a set of values that we must adhere to at all times: Integrity and Transparency Uphold the highest standards of integrity and transparency in all our conversations. Safety Remain committed to providing safe working environments through continuous improvements of our infrastructure, work practices and behaviors. Quality Be dedicated to designing quality into our products and processes to delight our stakeholders. Productivity Strive to achieve more with less through a culture of innovation, continuous improvements and sustained focus on elimination of waste. Respect for the Individual Stay committed to creating a work environment that encourages diverse perspectives and upholds the dignity of work and of individuals. Collaboration and Teamwork Leverage expertise and resources from across our global network to create greater value for our stakeholders. Sustainability Create value for all our stakeholders in a manner that respects our natural environment and serves the best interests of the communities in which we live and work. PAGE 4 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20

OUR BEHAVIORS Our brand is not just what we say. It is what we do. It is what our customers experience from us. Our behavior must be consistent in order for us to deliver on our promises and live our brand belief across all touchpoints. The more focused and inspired our behavior is, the stronger the bond, the richer the relationship with our customers. To help us be consistent, we have identified a set of 5 behaviors. These are: Reach out to understand Be empathetic to the needs of our people, partners and patients. Engage meaningfully, going beyond the stated and the obvious to develop a holistic view of their needs. Be the first to respond and the fastest to act Have a sense of urgency in the way we think, act and communicate. Create simple plans and processes and take ownership for their timely execution. Do things differently Innovate in ways which are meaningful. Spot opportunities, experiment, take risks, empower our teams and find a way to tackle the toughest challenges. Simplify Question and eliminate what is not essential within our systems, processes, roles and communications to become ever more dynamic and human. Create shared success Create a culture that values teamwork while acknowledging individual excellence. Collaborate across our businesses and with our partners to create shared value. PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20 PAGE 5

Dr. Reddy s in the US at a Glance: Global Offices - Australia, Belarus, Brazil, Canada, China, Colombia, Germany, India, Jamaica, Japan, Kazakhstan, Mexico, Myanmar, Netherlands, New Zealand, Romania, Russia, Sri Lanka, South Africa, Switzerland, Ukraine, Uzbekistan, Venezuela, Vietnam, UK, USA Research & Development Centers - India, Netherlands, UK, USA Manufacturing Facilities - India, China, Mexico, USA Headquarters - India Prescription products: 60+ products are marketed under the Dr. Reddy s label in 280+ dosing presentations. Over-The-Counter products: 5 products are marketed in 150+ store-brand packaging presentations (private label). Robust pipeline in various stages of development: 76 ANDAs are pending, of which 50 are Para IV certifications and 18 FTFs. Dosage forms: Oral solids, injectables, liquids, topicals, patches and other forms are available. 33 of our prescription products are ranked among the top 3 in market share. Dr. Reddy s is ranked among the top 10 corporations in Total Prescriptions dispensed* *IMS Health, National Prescription Audit September 2015 PAGE 6 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20

General Overview of Fellowship The Dr. Reddy s Laboratories Post-Doctoral Pharmaceutical Industry Fellowship is intended to provide a comprehensive multi-disciplinary experience for PharmD graduates who desire to focus and accelerate their career in the Pharmaceutical Industry. Fellows will have the opportunity to gain first-hand knowledge in multiple functional areas. The focus will be Pharmacovigilance and Medical Affairs with exposure to other disciplines. The fellow will be a fully integrated part of Dr. Reddy s Laboratories reporting to the Global Head - Pharmacovigilance and the Head of Medical Affairs North American Generics and Canada. Responsibilities will be focused in the US and Canada. The fellow will develop a thorough understanding of the operations in Pharmacovigilance and in Medical Affairs in the US and how it differs from our other geographies. Daily Operational Responsibilities Within Medical Affairs for North America, the fellows may learn the daily responsibilities of Medical Information and Promotional Review for prescription and over the counter products, train Nurse Educators/Medical Science Liaisons, support labeling updates with Regulatory Affairs, and engage with Quality Assurance and Supply Chain for product complaints. The fellow will gain real life experience while learning the necessities to successfully manage Medical Affairs activities for a global generics company. As defined by the World Health Organization, Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. Within Dr. Reddy s Pharmacovigilance, the fellow will be trained in the skills necessary for compliance with global post-marketing and clinical trial adverse event report regulations, the creation of aggregate safety reports such as PADERs/PSURs/PBRERs, and learn the complexities of signal management for generic and branded prescription and over-the-counter drugs, biosimilars and devices in a global environment. Additionally, fellows will also get the opportunity to have hands on learning experiences across a variety of safety initiatives such as patient registry & support programs, medication take-back programs and complex multi-sponsor REMS programs. Training on vendor management, validation, understanding compliance, management of safety database(s)and electronic submission to Regulatory Authorities will also be required. If desired, the fellow could also be exposed to Clinical Operations activities involving protocol development, study start up investigation meeting requirements, risk-based study monitoring and preparation of final study report. Throughout the fellowship, the fellow will collaborate with various cross-functional teams. In essence, the fellow will gain working knowledge in all areas of global clinical and post-marketing Pharmacovigilance and Drug Safety. PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20 PAGE 7

Since joining Dr. Reddy s Fellowship Program, I have had the unique opportunity to work on a multitude of cross-functional projects ranging from department to corporate level. The experience, education, and level of responsibility I have received in such a short amount of time has been absolutely invaluable. The relationships I have built have been exceptional and very fulfilling. Those around me have taken a genuine interest in my personal goals and allowed me to branch out and work on projects in focus areas other than my own. This has allowed me to experience different aspects of the pharmaceutical industry and develop a deeper understanding and appreciation for the many cogs required to make the machine work in an effective and efficient manner. Moreover, this has opened my eyes to the many potential career options where my skill set and interests coincide, that which I had not previously received exposure or considered. This is truly an extraordinary opportunity where you can let your own ambition take the wheel and guide you however far you desire. Confidently, expect great things from everyone involved in the program, just as we expect great things from you. I sincerely look forward to meeting and working closely with next year s class of fellows. Anthony J Marti, PharmD, MBA Dr. Reddy s Fellow, 2017-2019 The Dr. Reddy s multi-disciplinary fellowship has provided me with a unique opportunity to gain experience in both medical affairs and pharmacovigilance in an industry setting. This program allows the fellow to work in close proximity with other departments, all while establishing understandings of the various complexities associated with the marketing or launch of products. Fellows are able to gain hands-on experiences, while being able to take the lead on impactful projects. I have been included on several major cross-functional projects in multiple therapeutic areas. The support and mentorship I have received thus far in the program has been instrumental in both my personal and professional growth. I am confident this experience will provide me with the skill set I need in order to be an effective and successful professional within the pharmaceutical industry. Mahima Chojar, PharmD Dr. Reddy s Fellow, 2017-2019 PAGE 8 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20

I have learned so much in such a short time since beginning The Dr. Reddy s Fellowship Program. These past few months at Dr. Reddy s have been great. I have learned a lot about Pharmacovigilance, and I am so excited to work with other departments over the next year. In addition to learning about the Pharmaceutical Industry I have received career development training that I will utilize during my entire professional life. I am confident that choosing this fellowship will prepare me for a career within the Pharmaceutical Industry. Urvi Patel, PharmD Dr. Reddy s Fellow, 2016-2018 Choosing The Dr. Reddy s Fellowship was the best decision. I have been given so many opportunities and have been included in many projects while in Medical Affairs. I have grown exponentially since joining. Being exposed to so many cross functional teams has helped me build skills and friendships that will last forever. I am very excited to explore all the areas within the Pharmaceutical Industry this fellowship offers. Shalon Jones MPH, PharmD Dr. Reddy s Fellow, 2016-2018 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20 PAGE 9

Potential Activities MEDICAL INFORMATION Call center inquiry processing work alongside a Medical Information Associate (MIA) to intake Medical Inquiries (MI), Adverse Events (AE) and Product Complaints (PC) AE case processing using a validated safety database PC retrieval kit processing Writing standard response documents POST-MARKETING PV AE Reporting PADER creation REMS participation and monitoring Signal Detection CLINICAL PV Protocol review Trial site evaluation and monitoring visit MEDICAL AFFAIRS Promotional Review Committee Labeling Committee Medical Writing PAGE 10 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20

One-Year Rotation in Each Department: PHARMACOVIGILANCE Develop working knowledge and practice of global drug, biosimilar and device safety rules and regulations during clinical trials Develop working knowledge and practice of global drug, biosimilar and device safety rules and regulations for approved products Develop working knowledge and practice of various validated technologies and database tools used to support Pharmacovigilance Become proficient at Signal Management Liaise with internal colleagues to interpret safety data to perform benefit: risk assessments Write, review and analyze individual case safety reports and aggregate safety reports Review study protocols and clinical trial data for Adverse Events Actively participate in patient registry, support programs and multi-sponsor REMS programs Assist in the training of adverse event reporting for new hires MEDICAL AFFAIRS Respond to medical inquiries from Health Care Provider (HCP) and patients Develop scientifically accurate medical responses to unsolicited medical information inquiries Create standard responses to FAQs to respond to unsolicited medical inquiries from patients and consumers Assist in developing claims for OTC products, including Rx-to-OTC switches Assist in the development, review and approval of labeling activities Train Medical Information call center staff Participate in the medical review of promotional and non-promotional materials Participate in medical slide content development and review Serve as a subject matter expert on the selected disease state PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20 PAGE 11

Program Directors Karin Greenberg, BS Pharm, RPh, PharmD, BCPS Global Head Pharmacovigilance Ernest Mario School of Pharmacy Graduate Dr. Karin A. Greenberg is a graduate of Rutgers University, Ernest Mario School of Pharmacy (BS Pharmacy; 1993 and Doctorate of Pharmacy; 1995) who is a licensed pharmacist in 2 states (NJ and NY). Karin completed her Post-Doctoral Residency (Drug Safety & Medical Affairs) with Janssen Pharmaceuticals in 1996. She also has her Board Certification in Pharmacotherapy Specialties (BCPS) since 1999. PROGRAM DIRECTORS Joy Kainer, BS Pharm, RPh, PharmD Head Medical Affairs North American Generics and Canada Ernest Mario School of Pharmacy Graduate Dr. Joy Kainer is a graduate of Rutgers University, Ernest Mario School of Pharmacy (BS Pharmacy; 1989) and received her Doctorate of Pharmacy from Shenandoah University, Bernard J. Dunn School of Pharmacy in 2008 and is a registered pharmacist in New Jersey since 1989. With more than 25 years of experience beginning as a retail pharmacist, Joy has more than 20 years of pharmaceutical industry experience focused on Medical Affairs, in particular Medical Communications and Medical Information, Investigator Initiated Grants and Continuing Education Grants, Publication Strategy and Promotional Review Committee, and Sales Training. PAGE 12 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20

Advising Faculty Amrit Gill, MD, MBA Director, Pharmacovigilance and Risk Management Strategy North America ADVISING FACULTY Shahida Hasan, MD Associate Director, Clinical Pharmacovigilance, North America Min Gong, PharmD Manager, Medical Affairs North America PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20 PAGE 13

Job Requirements: Knowledge of product development with strong clinical background (clinical trials, Pharmacovigilance, Medical Affairs, vendor management, budgeting, auditing) Knowledge of appropriate worldwide assessment of benefit risk management, medical evaluation of Individual Case Safety Reports, signal detection strategies, evaluation of safety signals and formulation of responses to regulatory inquiries on product safety issues. Strong decision making and problem solving abilities as well as excellent time management, data research and situation analysis proficiencies. Upon completion of the fellowship, you will have a working knowledge of the following: Medical Affairs/Product Development Excellent Presentation Skills Clinical Outcomes Experience Medical Evaluation Medical Safety Analysis & Reporting US and EU pharmacovigilance regulatory requirements Healthcare Management & Administration Counseling & Training for Medical Information and Pharmacovigilance Drug Safety & Adverse Event Reporting Single Case Reviews Experience with ARGUS, ARISg, AdEERS, Clintrace. Good knowledge of ICH GCP compliance Vendor Management/Vendor Training Compensation and Benefits: The selected fellows will be offered a highly competitive salary and benefits. PAGE 14 PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20

Application Process and Eligibility Requirements To be considered for the Dr. Reddy s Fellowship Program, you must meet the following criteria: Be a graduate of an accredited Doctor of Pharmacy Program prior to the start date of the fellowship term Have a strong interest in pursuing a career in the pharmaceutical industry Be a U.S. citizen or lawful permanent resident Application Deadlines: Complete on-line application at http://app.jobvite.com/m?3ryw8jwr Curriculum Vitae (Resume) Initial Interview (by phone) Letter of Intent Official College Transcript Three Letters of Recommendation Secondary Interview (on site) November 1 st - December 1 st 2017 November 1 st - December 1 st 2017 December 11 th - December 22 nd 2017 January 5 th 2018 January 5 th 2018 January 5 th 2018 January 8 th - January 19 th 2018 Application Information Two fellows will be selected for the 2-Year Multi-disciplinary program. Applications should be sent to Dr. Reddy s Medical Affairs, North America at drlma@drreddys.com PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM 2018-20 PAGE 15

Dr. Reddy s Laboratories, Inc. 107 College Road East, Princeton, NJ, 08540 (609) 375-9900 www.drreddys.com